CMPX stock · KEYS stock

CMPX vs KEYS

Compass Therapeutics Inc. (CMPX) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.

Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on US.

Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.

CMPX does not have a complete income-statement cache yet.

Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.

CMPX currently screens at market cap $367.4M. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.

Not investment advice. Open the CMPX and KEYS stock pages for the full models.

Not investment advice.

Popular Stock Comparisons